Table 1
Comparison of key features among three thrombolytic agents for clinical use or trial in acute ischaemic stroke
| Alteplase | Tenecteplase | Non-immunogenic staphylokinase | |
| Structure |
|
Thr103→Asn, Asn117→Gln, Lys296-His-Arg-Arg→Ala-Ala-Ala-Ala |
Lys74→Ala, Glu75→Ala, Arg77→Ala |
| Molecular weight | 70 kDa | 70 kDa | 16.5 kDa |
| Dose and administration | 0.9 mg/kg (≤90 mg) 10% bolus and 90% infusion over 60 min | 0.25 mg/kg (≤ 25 mg) Single bolus | 10 mg Single bolus |
| Fibrin-selectivity | Low | High | High |
| Inhibition by PAI | Yes | No | No |
| Plasminogen activation | Direct | Direct | Indirect |
| Half-life | 5 min | 22 min | 6 min |
| Immunogenicity | No | No | No |
| Cost | High | High | Low |
| Treating acute ischaemic stroke | Clinical use | Clinical trial | Clinical trial |
PAI, plasminogen activator inhibitor.